Notably, a study of the use of EGFR inhibitors in colorectal cancer tumors with mutations and sotorasib resistance found that upregulation of EGFR was a common resistance mechanism, and dual targeting of EGFR and KRAS blocked acquisition of resistance (14). The gene discussed is EGFR; the disease is colorectal cancer.